Ral GTPases and cancer: linchpin support of the tumorigenic platform - PubMed (original) (raw)
Review
doi: 10.1038/nrc2296.
Affiliations
- PMID: 18219307
- DOI: 10.1038/nrc2296
Review
Ral GTPases and cancer: linchpin support of the tumorigenic platform
Brian O Bodemann et al. Nat Rev Cancer. 2008 Feb.
Abstract
A confluence of recent observations has indicted the Ras-family G-proteins RALA and RALB as key offenders in the subversion of core biological systems driving oncogenic transformation. Here, we will focus on current developments highlighting the pivotal contribution of Ral proteins to the regulatory framework supporting tumorigenesis, and evaluate mechanistic connections between Ral effector activation and generation of this framework.
Similar articles
- Ral GTPases: corrupting the exocyst in cancer cells.
Camonis JH, White MA. Camonis JH, et al. Trends Cell Biol. 2005 Jun;15(6):327-32. doi: 10.1016/j.tcb.2005.04.002. Trends Cell Biol. 2005. PMID: 15953551 Review. - Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.
Lim KH, O'Hayer K, Adam SJ, Kendall SD, Campbell PM, Der CJ, Counter CM. Lim KH, et al. Curr Biol. 2006 Dec 19;16(24):2385-94. doi: 10.1016/j.cub.2006.10.023. Curr Biol. 2006. PMID: 17174914 - Ral GTPases in tumorigenesis: emerging from the shadows.
Kashatus DF. Kashatus DF. Exp Cell Res. 2013 Sep 10;319(15):2337-42. doi: 10.1016/j.yexcr.2013.06.020. Epub 2013 Jul 2. Exp Cell Res. 2013. PMID: 23830877 Free PMC article. Review. - Expression of ral GTPases, their effectors, and activators in human bladder cancer.
Smith SC, Oxford G, Baras AS, Owens C, Havaleshko D, Brautigan DL, Safo MK, Theodorescu D. Smith SC, et al. Clin Cancer Res. 2007 Jul 1;13(13):3803-13. doi: 10.1158/1078-0432.CCR-06-2419. Clin Cancer Res. 2007. PMID: 17606711 - Ral: mediator of membrane trafficking.
van Dam EM, Robinson PJ. van Dam EM, et al. Int J Biochem Cell Biol. 2006;38(11):1841-7. doi: 10.1016/j.biocel.2006.04.006. Epub 2006 May 9. Int J Biochem Cell Biol. 2006. PMID: 16781882 Review.
Cited by
- Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?
Healy FM, Turner AL, Marensi V, MacEwan DJ. Healy FM, et al. Front Pharmacol. 2024 Sep 20;15:1441938. doi: 10.3389/fphar.2024.1441938. eCollection 2024. Front Pharmacol. 2024. PMID: 39372214 Free PMC article. Review. - A let-7 microRNA-RALB axis links the immune properties of iPSC-derived megakaryocytes with platelet producibility.
Chen SJ, Hashimoto K, Fujio K, Hayashi K, Paul SK, Yuzuriha A, Qiu WY, Nakamura E, Kanashiro MA, Kabata M, Nakamura S, Sugimoto N, Kaneda A, Yamamoto T, Saito H, Takayama N, Eto K. Chen SJ, et al. Nat Commun. 2024 Mar 22;15(1):2588. doi: 10.1038/s41467-024-46605-0. Nat Commun. 2024. PMID: 38519457 Free PMC article. - RAS-targeted cancer therapy: Advances in drugging specific mutations.
Liu C, Ye D, Yang H, Chen X, Su Z, Li X, Ding M, Liu Y. Liu C, et al. MedComm (2020). 2023 May 27;4(3):e285. doi: 10.1002/mco2.285. eCollection 2023 Jun. MedComm (2020). 2023. PMID: 37250144 Free PMC article. Review. - Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS.
Yin G, Huang J, Petela J, Jiang H, Zhang Y, Gong S, Wu J, Liu B, Shi J, Gao Y. Yin G, et al. Signal Transduct Target Ther. 2023 May 23;8(1):212. doi: 10.1038/s41392-023-01441-4. Signal Transduct Target Ther. 2023. PMID: 37221195 Free PMC article. Review. - Regulation of Ras p21 and RalA GTPases activity by quinine in mammary epithelial cells.
Bhatia V, Esmati L, Bhullar RP. Bhatia V, et al. Mol Cell Biochem. 2024 Mar;479(3):567-577. doi: 10.1007/s11010-023-04725-z. Epub 2023 May 2. Mol Cell Biochem. 2024. PMID: 37131040
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources